Showing 40,001 - 40,020 results of 102,873 for search '(( i ex decrease ) OR ( 5 ((point decrease) OR (((mean decrease) OR (a decrease)))) ))', query time: 1.54s Refine Results
  1. 40001
  2. 40002
  3. 40003
  4. 40004
  5. 40005
  6. 40006
  7. 40007
  8. 40008
  9. 40009
  10. 40010

    Thermodynamic parameters. by Jianqing Jia (21001506)

    Published 2025
    “…Consequently, tunnel reliability decreases. Specifically, with temperature increases of 2.6 °C and 4 °C, tunnel reliability decreases by approximately 4.5% and 6.3%, respectively, when considering insulation layer deterioration.…”
  11. 40011

    Alteration of Pituitary Tumor Transforming Gene-1 Regulates Trophoblast Invasion via the Integrin/Rho-Family Signaling Pathway by Seung Mook Lim (2267395)

    Published 2016
    “…Furthermore, knockdown of PTTG1 increased expression of integrin alpha 4 (ITGA4), ITGA5, and integrin beta 1 (ITGB1); otherwise, RhoA expression was significantly decreased (<i>p <</i> 0.05). …”
  12. 40012

    Table_1_Dysregulation of Principal Circulating miRNAs in Non-human Primates Following Ischemic Stroke.XLSX by Jian Chen (15340)

    Published 2021
    “…For example, mml-miR-191-5p, miR-421, miR-409-5p, and let-7g-5p were found to be significantly overexpressed, whereas mml-miR-128a-5p_R − 2, miR-431_R − 1, and let-7g-3p_1ss22CT were significantly downregulated. …”
  13. 40013

    Trends in use of prescription stimulants in the United States and Territories, 2006 to 2016 by Brian J. Piper (412361)

    Published 2018
    “…</p><p>Results</p><p>Amphetamine use increased 2.5 fold from 2006 to 2016 (7.9 to 20.0 tons). Methylphenidate use, at 16.5 tons in 2006, peaked in 2012 (19.4 tons) and subsequently showed a modest decline (18.6 tons in 2016). …”
  14. 40014
  15. 40015
  16. 40016
  17. 40017

    Image_2_A Phase 1 Dose-Escalation Study of PF-06671008, a Bispecific T-Cell-Engaging Therapy Targeting P-Cadherin in Patients With Advanced Solid Tumors.tif by James J. Harding (12415627)

    Published 2022
    “…Adult patients with treatment-refractory solid tumors received PF-06671008 (1.5–400 ng/kg) as a weekly intravenous (IV) infusion on a 21-day/3-week cycle. …”
  18. 40018

    Image_1_A Phase 1 Dose-Escalation Study of PF-06671008, a Bispecific T-Cell-Engaging Therapy Targeting P-Cadherin in Patients With Advanced Solid Tumors.tif by James J. Harding (12415627)

    Published 2022
    “…Adult patients with treatment-refractory solid tumors received PF-06671008 (1.5–400 ng/kg) as a weekly intravenous (IV) infusion on a 21-day/3-week cycle. …”
  19. 40019

    Supplementary Material for: Mortality and Cardiovascular Morbidity Associated with Haemoglobin Levels: A Pooled Analysis of Randomised Controlled Trials by Locatelli F. (3698788)

    Published 2017
    “…<b><i>Results:</i></b> Average Hb <10 g/dl, decrease from stable baseline Hb >1 g/dl, last Hb <10 g/dl, Hb decline >1.5 g/dl/4 weeks and increased Hb variability were associated with a higher risk of the composite end point and all-cause mortality. …”
  20. 40020